Timothy P. Rearden

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer.

Eric J. Small, S. Srinivas, Barbara Egan et al. · Journal of Clinical Oncology · 1996 · 50 citations

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Andrew A. Davis, Jingqin Luo, Tiantian Zheng et al. · Clinical Cancer Research · 2023 · 44 citations · Full text

Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer

Douglas Adkins, Robert W. Brown, K. Trinkaus et al. · Journal of Clinical Oncology · 1999 · 43 citations

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Foluso O. Ademuyiwa, Ina Chen, Jingqin Luo et al. · Breast Cancer Research and Treatment · 2021 · 35 citations · Full text

Breast Oncology, Medicine, Immunology +10

Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA)

Timothy P. Rearden, Veena Charu, Bruce Saidman et al. · Journal of Clinical Oncology · 2004 · 19 citations

Immunohematology, Pharmacotherapy, Metronomic Chemotherapy +20